Iovance Biotherapeutics, Inc.

Name: Iovance Biotherapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

IOVANasdaqCIK 1425205HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$99.3m, Q2 FY2026

Operating income−$51.9m, Q2 FY2026

Net income−$47.3m, Q2 FY2026

Iovance Biotherapeutics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.5	0.5	0.7	31.1	58.6	73.7	49.3	60.0	67.5	86.8	71.4	99.3
Cost of revenue	$m	4.3	(5.4)	7.3	31.4	31.5	37.8	42.7	48.9	38.5	43.1	42.5	43.6
Research and development	$m	87.5	76.6	79.8	62.1	67.0	71.0	76.0	77.9	75.2	71.2	62.5	58.9
Operating income	$m	(118)	(121)	(118)	(102)	(89.1)	(86.6)	(121)	(114)	(94.9)	(73.5)	(81.0)	(51.9)
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$m	(1.2)	(1.8)	(1.4)	(1.5)	(1.5)	1.6	(1.8)	2.0	(2.4)	0.2	(0.7)	(1.4)
Net income	$m	(114)	(116)	(113)	(97.1)	(83.5)	(78.6)	(116)	(112)	(91.3)	(71.9)	(79.0)	(47.3)
Diluted EPS	$ per share	(0.46)	not reported	(0.42)	(0.34)	(0.28)	not reported	(0.36)	(0.33)	not reported	not reported	(0.19)	(0.11)
Basic EPS	$ per share	(0.46)	not reported	(0.42)	(0.34)	(0.28)	not reported	(0.36)	(0.33)	(0.25)	not reported	(0.19)	(0.11)

Balance sheet

Cash and equivalents$110.8m, Q2 FY2026

Shareholders' equity$736.0m, Q2 FY2026

Iovance Biotherapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	268	115	134	229	164	116	172	132	158	163	197	111
Current assets	$m	383	308	386	482	499	457	513	423	429	443	467	464
Total assets	$m	852	780	870	964	991	910	967	907	905	913	926	916
Current liabilities	$m	91.0	110	83.2	93.6	118	122	123	129	126	138	129	107
Total liabilities	$m	178	196	190	196	218	200	199	209	203	215	204	179
Shareholders' equity	$m	674	585	680	769	773	710	768	698	702	699	722	736

Cash flow

Operating cash flow−$60.8m, Q2 FY2026

Capital expenditure$5.4m, Q2 FY2026

Iovance Biotherapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(84.1)	(84.0)	(122)	(98.4)	(59.0)	(73.3)	(104)	(67.4)	(78.7)	(52.6)	(72.1)	(60.8)
Capital expenditure	$m	3.6	3.5	4.2	0.4	2.3	4.2	6.2	7.5	10.8	9.3	6.6	5.4

Diluted shares (weighted)450,189, Q2 FY2026

Iovance Biotherapeutics, Inc., shares, quarterly
Line item	Unit	Q2 FY20222022-06-30	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	157	158	214	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.4	0.5

Shares outstanding: 452.97m at Jul 29, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. Listed shows no prices and gives no investment advice.